Amyloidosis - 258 Studies Found

Active, not recruiting : Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis
: Primary Amyloidosis of Light Chain Type
: 2012-01-11
: Drug: Pomalidomide and Dexamethasone Pomalidomide: 2-4mg/day, every day in cycles of 28 days until progr
Suspended : High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease
: Primary Amyloidosis of Light Chain Type
: 2012-01-11
:
  • Device: High Cut-off Hemodialysis

Not yet recruiting : Study in Subjects With Light Chain (AL) Amyloidosis
: AL Amyloidosis
: 2017-04-28
: Drug: NEOD001 humanized monoclonal antibody
Active, not recruiting : The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
: AL Amyloidosis
: 2015-12-09
:
  • Drug: NEOD001 NEOD001 is a mon
Active, not recruiting : Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
: AL Amyloidosis
: 2015-11-18
: Drug: NEOD001 NEOD001
Completed : A Trial for Systemic Light-chain (AL) Amyloidosis
: AL Amyloidosis
: 2011-01-10
: Drug: BMDex BMDex:
Completed : Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis
:
  • Amyloidosis
  • Primary Amyloidosis

: 2015-09-16
Suspended : First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
:
  • Light Chain Deposition Disease
  • Primary Systemic Amyloidosis : 2012-11-13
    :
    • Drug: pomalidomide Given PO
Completed : A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis
: Primary Amyloidosis
: 2009-04-15
: Drug: Lenalidomide Up to 6 cycles of oral L-Mel-Dex, every 28 days Revlimid® 10 mg daily for 21 day
Completed : Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis
: Amyloidosis
: 2016-03-14
:
  • Other: blood collection
  • Other: bone marrow
<<< Previous | Next >>>